


ASCO24

TOP TEN BY ONCOALERT

LEUKEMIA



OncoAlert³⁶⁰
Oncology For Colleagues By Colleagues

WWW.ONCOALERT360.COM

6504

BECABTAGENE AUTOLEUCEL IN ADULTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): OS, EFS AND THE POTENTIAL IMPACT OF CAR-T CELL PERSISTENCY AND CONSOLIDATIVE STEM CELL TRANSPLANTATION: FELIX

6501

PONATINIB (PON) IN PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) AND THE T315I MUTATION (MUT): 4-YEAR RESULTS FROM OPTIC.

**LBA
6500**

ASC4FIRST, A PIVOTAL PHASE 3 STUDY OF ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS TKIS) IN NEWLY DIAGNOSED PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): PRIMARY RESULTS.

6528

OLUTASIDENIB FOR MUTATED IDH1 ACUTE MYELOID LEUKEMIA: FINAL FIVE-YEAR RESULTS FROM THE PHASE 2 PIVOTAL COHORT.

6541

SAFETY AND EFFICACY OF LISAFTOCLAX, A NOVEL BCL-2 INHIBITOR, IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH TREATMENT-NAÏVE OR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.

**TPS
6594**

PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY EVALUATING SELINEXOR, AN XPO1 INHIBITOR, PLUS RUXOLITINIB IN JAKI-NAÏVE MYELOFIBROSIS

6509

PRELIMINARY SAFETY AND EFFICACY OF ORAL AZACITIDINE (ORAL-AZA) IN PATIENTS (PTS) WITH LOW-/INTERMEDIATE (INT)-RISK MYELODYSPLASTIC SYNDROMES (MDS): PHASE 2 RESULTS FROM THE ASTREON TRIAL.

6502

UPDATED SAFETY AND EFFICACY DATA FROM THE PHASE 3 MANIFEST-2 STUDY OF PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS.

6514

IMPACT OF JAK2 ALLELE BURDEN ON MF OUTCOME IN THE ERA OF RUXOLITINIB.

6538

OUTCOMES OF PATIENTS WITH BONE MARROW FIBROSIS IN DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA.

Leads



Dr Haddad
Heme/Med Onc



Dr Morgan
Clin Onc